Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma (NCT06118086)
A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
Who can join: Review the eligibility criteria below.
Location: University of California San Francisco Helen Diller Comprehensive Cancer Center — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- University of California San Francisco Helen Diller Comprehensive Cancer Center — San Francisco, California
- Moffitt Cancer Center — Tampa, Florida
- Dana Farber Cancer Research Institute — Boston, Massachusetts
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- Sarah Cannon Research Institute — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- Centre Antoine Lacassagne — Nice,
- Institut de Cancerologie Gustave-Roussy — Villejuif,
📞 Contact the Study Coordinator
Phone: (781) 827-0902
Email: ClinicalTrials@remixtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Adenoid Cystic Carcinoma
- Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma — Basking Ridge, New Jersey
- Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers — Miami, Florida
- Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial — San Francisco, California
- A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma — Basking Ridge, New Jersey
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC — Boston, Massachusetts
Explore by condition: All Adenoid Cystic Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.